Intracranial hypertension is a life-threatening condition that can arise from a wide variety of neurological disorders, including traumatic brain injury (TBI), stroke, tumor, and infection as well as general medical illnesses, such as hepatic encephalopathy. Local mass effect, vasogenic and cytotoxic edema, inflammation, and bloodbrain barrier disruption are among the factors that can lead to brain herniation, permanent neurological injury, and death. Against these forces, the body fights back by raising perfusion pressure to keep the effects of elevated intracranial pressure (ICP) at bay. This is no easy task. In a closed-volume system, pressure rises rapidly once compliance runs out. Physicians enter the fray by attempting to alter the fundamental principle of ICP dynamics described by the Monro-Kellie doctrine, which states that in the fixed cranial space, the brain, CSF, and intracranial blood volume are in equilibrium, in which one cannot be altered without affecting the others. Given the prevalence of intracranial hypertension in TBI, much of the research on treatment of elevated ICP has come from the trauma literature. This research is reflected in the guidelines for the treatment of TBI.
Intracranial hypertension is a life-threatening condition that can arise from a wide variety of neurological disorders, including traumatic brain injury (TBI), stroke, tumor, and infection as well as general medical illnesses, such as hepatic encephalopathy. Local mass effect, vasogenic and cytotoxic edema, inflammation, and bloodbrain barrier disruption are among the factors that can lead to brain herniation, permanent neurological injury, and death. Against these forces, the body fights back by raising perfusion pressure to keep the effects of elevated intracranial pressure (ICP) at bay. This is no easy task. In a closed-volume system, pressure rises rapidly once compliance runs out. Physicians enter the fray by attempting to alter the fundamental principle of ICP dynamics described by the Monro-Kellie doctrine, which states that in the fixed cranial space, the brain, CSF, and intracranial blood volume are in equilibrium, in which one cannot be altered without affecting the others. Given the prevalence of intracranial hypertension in TBI, much of the research on treatment of elevated ICP has come from the trauma literature. This research is reflected in the guidelines for the treatment of TBI. 1 The mainstay of medical treatment is osmotic diuresis, which has been traditionally accomplished with mannitol, a sugar alcohol that increases the osmolarity of blood, creating an osmotic gradient that pulls free water from the brain, thereby reducing brain volume. Although mannitol is clearly effective in treating many cases of elevated ICP, its use has several drawbacks. Among these are the hypovolemia that occurs as the mannitol is cleared by the kidneys, taking intravascular fluid with it, as well as the interstitial deposition of mannitol over time, which can result in a reverse osmotic gradient. Over the past decade, hypertonic saline (HTS) solutions have emerged as an alternative to mannitol. Increasing the osmolarity of blood with NaCl can establish the necessary osmolar gradient to treat elevated ICP. Hypertonic saline increases blood volume and does not cross the blood-brain barrier as easily as mannitol does, making it a treatment worth investigating.
In their article in this issue of the Journal of Neurosurgery, Mortazavi and colleagues 2 have written a comprehensive review of 36 papers on HTS therapy and a meta-analysis on the use of HTS versus mannitol for the treatment of intracranial hypertension. This work is an important contribution to the literature for several reasons. It provides a broad overview of the many applications for this novel tool and attempts to demonstrate empirically the utility of HTS for elevated ICP-a great undertaking. An earlier attempt by Ogden and colleagues 3 in 2005 faced many of the same issues and could only conclude that HTS therapy was useful, but needed better definition. The literature contains reports that vary greatly in regard to the origin of raised ICP, concentration of HTS used, method of administration (bolus vs drip), study design, and study end points. The authors of the current study use these distinctions to categorize the studies and then examine each grouping, paying special attention to the findings of randomized controlled trials. Although comprehensive, this process is cumbersome. Although the majority of the studies support the hypothesis that HTS is effective at reducing raised ICP, it is difficult to follow the methodology of each individual study. Does the prospective study that looked at HTS boluses in subarachnoid hemorrhage (SAH) use the daily number of episodes of ICP > 20 mm Hg or the 1-year Glasgow Outcome Scale score as a measure of success? However, in the absence of large, randomized studies with standardized end points, the authors' work is an admirable first step.
In the meta-analysis, the authors pool data from 8 randomized controlled trials that compared HTS with mannitol. Not surprisingly, the definition of failure of treatment is different for each study. Still, combining the studies, the analysis yielded only 19 of 117 failures in patients or episodes in the HTS group compared with 39 of 113 in the mannitol group. Again, it is difficult to draw specific conclusions about the indications and best methods of administration for HTS therapy from this analysis.
Hypertonic saline is an extremely promising treatment for intracranial hypertension. Before we declare that HTS is a fine treatment that all patients need, further study must be done. Although HTS seems to be effective overall, the nuances of its use have not been fully elucidated. Is HTS a better treatment for conditions such as SAH and polytrauma, in which hypovolemia should be avoided, than for other causes of intracranial hypertension? What is the optimal concentration and length of treatment? Finally, and perhaps most importantly, what effects will HTS therapy have on the long-term outcome of patients? Given the frequency of intracranial hypertension in neurological conditions, a great opportunity exists for collaborative research, perhaps starting with an Internet database to collect data (similar to the Hypother- [Accessed August 17, 2011]) and leading to well-designed, well-powered trials that account for the many complexities of HTS therapy. Unless good studies such as this one are undertaken, we will never find the answers we seek.
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